The whole deal management in a single interface
Data room management alongside the AI due diligence report, and surface the evidence behind any claim without leaving the page.
Conditional
Source confidence
62
Uploaded files
Revonode report
Does the Phase 2 data support the efficacy claim in the deck?
Revonode
Partly. The deck claims a 68% responder rate; the study report gives 68% for the 100 µg arm only, n=23, with no active comparator. The pooled figure across all arms is 54%. Two of the three cited supporting papers sit behind programmes that failed in humans — down-weighted, not hidden.
Due diligence report
Ilvaren Bio
01 · Executive summary
Ilvaren Bio presents a late-stage RNAi asset with credible oncology positioning. Efficacy evidence is real but narrower than presented, and the CMC record has one material gap. Recommendation is conditional on resolving the comparator question.
02 · Evidence ledger
| Claim | Source | Grade |
|---|---|---|
| Orphan designation filed | Deck slide 11 | Gap |
Illustrative dataset — the interface is live, the deal is invented.
Every answer carries its receipt
An answer you cannot check is not diligence. Every claim the platform makes is traced to the page it came from, not to a plausible-sounding summary. Open the receipt and you land on the source.
All seven dimensions, side by side
Science, clinical and safety, IP, manufacturing, regulatory, market and team — every asset scored across the same seven, from bound signals rather than sentiment. No dimension skipped because a specialist wasn't free, and no asset judged on a different basis from the one beside it.
| Dimension | Ilvaren Bio62Conditional · 3 open | Cardra Therapeutics60Conditional · 5 open | Kessendra Bio58Conditional · 2 open | Thexoria Therapeutics35No-go · 9 open |
|---|---|---|---|---|
| Science | ||||
| Clinical & safety | ||||
| IP / FTO | ||||
| CMC | ||||
| Regulatory | ||||
| Market | ||||
| Team | ||||
| Binding risk | No FTO opinion; delivery chemistry overlaps a third-party family. | No human efficacy data past Phase 1 — platform, not asset. | Crowded indication; two competitors ahead on the same target. | 9 unresolved questions; evidence base sits behind discontinued programmes. |
Each cell is clickable — it opens the signals behind that dimension. Illustrative dataset — the interface is live, the deal is invented.
Bring us a deal.
See the diligence in hours.
Hand us a live or past data room. We'll index it, cross-check it against the external record, and show you the gaps and risks.